Overview

CJC-1295 + DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) that incorporates a Drug Affinity Complex (DAC)—a reactive chemical group that forms a covalent bond with circulating albumin after injection. This albumin conjugation dramatically extends the peptide's plasma half-life from approximately 30 minutes (without DAC) to 6–8 days, enabling sustained elevation of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels with less frequent dosing.

The prolonged GH elevation produced by CJC-1295 + DAC differs fundamentally from the pulsatile pattern seen with non-DAC variants. Rather than amplifying discrete GH pulses, the DAC version creates a sustained baseline elevation in GH secretion, which can increase mean GH levels by 2–10 fold and IGF-1 levels by 1.5–3 fold over the dosing period. Clinical trials conducted by ConjuChem Biotechnologies demonstrated dose-dependent increases in GH and IGF-1 with weekly or biweekly subcutaneous injections of 30–60 mcg/kg.

This sustained release profile is both an advantage and a consideration. While the convenience of weekly dosing appeals to many users, the continuous GH stimulation does not fully replicate the natural pulsatile GH secretion pattern, which has led some practitioners to prefer the non-DAC version for more physiological GH release. Common applications include anti-aging protocols, body composition optimization, and recovery enhancement. Side effects may include water retention, joint stiffness, and transient insulin resistance due to the sustained nature of GH elevation.

Mechanism of Action

Modified GHRH Analog — DAC-Conjugated Half-Life Extension

CJC-1295 + DAC is a synthetic growth hormone-releasing hormone (GHRH) analog consisting of the first 29 amino acids of human GHRH (tetrasubstituted GRF 1-29) conjugated to a drug affinity complex (DAC) — a reactive succinimidyl ester of a maleimide propionic acid linker that covalently binds to albumin in vivo. Four amino acid substitutions at positions 2 (D-Ala), 8 (Gln), 15 (Ala), and 27 (Leu) confer resistance to dipeptidyl peptidase IV (DPP-IV) cleavage at the His2-Ala3 bond, which normally inactivates native GHRH within 5-7 minutes. The DAC-albumin conjugation extends the elimination half-life from minutes to approximately 5-8 days, enabling sustained GHRH receptor activation with weekly dosing (PMID: 16352683).

GHRH Receptor — Gs/cAMP/PKA Signaling Cascade

CJC-1295 binds the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells — a class B1 G protein-coupled receptor coupled to Gsalpha. Receptor activation stimulates adenylyl cyclase, increasing intracellular cAMP, which activates protein kinase A (PKA). PKA phosphorylates CREB (cAMP response element-binding protein), inducing transcription of the GH1 gene and stimulating GH exocytosis from dense-core secretory granules. The sustained receptor occupancy from DAC conjugation produces tonic GHRH signaling, elevating baseline GH pulsatility and mean 24-hour GH levels by 2-10 fold (PMID: 17018659).

IGF-1 Axis & Somatotroph Proliferation

Sustained GH elevation from CJC-1295 + DAC increases hepatic IGF-1 production through JAK2/STAT5b signaling in hepatocytes, with clinical trials demonstrating 1.5-3 fold increases in IGF-1 levels that persist for 6-14 days after a single subcutaneous injection. Chronic GHRH receptor stimulation also induces somatotroph hyperplasia through Pit-1 transcription factor upregulation, potentially increasing pituitary GH reserve capacity.

Continuous vs Pulsatile Signaling Considerations

The extended half-life of DAC-conjugated CJC-1295 produces continuous rather than pulsatile GHRH receptor activation, which may cause partial receptor desensitization through beta-arrestin-mediated internalization and GRK phosphorylation. This blunts the amplitude of individual GH pulses while elevating the interpulse nadir — a pattern distinct from physiological pulsatile GH secretion.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: CJC-1295 + DAC (Drug Affinity Complex)

Common Side Effects

• Injection site reactions: redness, swelling, itching, and induration at the injection site (reported in most users)
• Facial flushing and warmth sensation lasting 15–30 minutes post-injection
• Water retention and peripheral edema (dose-dependent; related to GH-mediated sodium retention)
• Headache, particularly during the first 1–2 weeks
• Numbness and tingling in extremities (paresthesia), especially in hands
• Joint stiffness and mild arthralgias
• Increased hunger and appetite stimulation

Serious Adverse Effects

• Prolonged GH elevation: the DAC (Drug Affinity Complex) modification extends half-life to 6–8 days, creating sustained, non-pulsatile GH release that may desensitize GH receptors and disrupt the natural GH/IGF-1 axis
• Carpal tunnel syndrome: sustained IGF-1 elevation promotes tissue swelling; reported at higher doses
• Insulin resistance: chronic GH elevation antagonizes insulin signaling; fasting glucose elevations and reduced glucose tolerance observed
• Potential tumor promotion: GH/IGF-1 axis stimulation is a known risk factor for proliferation of pre-existing malignancies (particularly colorectal, prostate, and breast); no direct evidence from CJC-1295 trials but biologically plausible
• Cortisol and prolactin elevation: GHRH analogs can modestly raise cortisol and prolactin; monitor if symptomatic
• Death report: one clinical trial participant death was reported during a 2006 clinical pharmacology study, though causality was not definitively established

Contraindications

• Active malignancy or history of cancer (especially hormone-sensitive cancers)
• Diabetic retinopathy or uncontrolled diabetes
• Active pituitary pathology (adenoma, hyperpituitarism)
• Pregnancy, planned pregnancy, or lactation
• Under 25 years of age (open growth plates; risk of acromegalic features)

Drug Interactions

• Insulin and oral hypoglycemics: GH-induced insulin resistance may necessitate increased diabetic medication doses
• Glucocorticoids: may blunt GH release and counteract CJC-1295 effects; conversely, GH may alter cortisol metabolism
• Other GH secretagogues (GHRP-6, ipamorelin, MK-677): stacking amplifies GH/IGF-1 elevation and all associated risks
• Somatostatin analogs (octreotide): directly antagonize GHRH signaling
• Thyroid hormones: GH increases T4→T3 conversion; may unmask hypothyroidism or require thyroid dose adjustment

Population-Specific Considerations

• This is a research peptide: CJC-1295 + DAC is not FDA-approved for any indication; all use is off-label/experimental
• Males vs. females: women may experience more pronounced water retention and joint symptoms due to hormonal interactions with estrogen
• Over 40 population: primary demographic; age-related GH decline makes this population more sensitive to both benefits and side effects
• Athletes: banned by WADA; detectable in anti-doping tests
• Monitoring: IGF-1 levels, fasting glucose, HbA1c, and prolactin should be checked at baseline and every 8–12 weeks

Pharmacokinetic Profile